FierceBiotechOriginal article
{"a":[{"_":"BioMarin axes $270M rare disease asset after missing phase 3 endpoint","$":{"href":"/biotech/biomarin-axes-270m-rare-disease-asset-after-missing-phase-3-endpoint","hreflang":"en"}}]}
Phase 3negativeBMN 401Negative
AI Analysis
Summary
BioMarin Pharmaceutical has terminated development of BMN 401 across all indications following mixed phase 3 data and failure to meet primary endpoints. The discontinued asset represents a $270M write-down for the company.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
missed phase 3 endpoint
Importance:7/10
Sentiment:
-0.85
phase 3 failureprogram terminationrare diseaseasset write-off
Related Companies
Read the original article
Published by FierceBiotech on August 7, 2026 8:59 AM